Fig. 3From: Promoter methylation of transient receptor potential melastatin-related 7 (TRPM7) predicts a better prognosis in patients with Luminal A breast cancersMethylation of TRPM7 predicted longer survival time in Lumina A breast cancer patients. The Kaplan–Meier estimator of the survivorship function was used to evaluate the impact of aberrant methylation of TRPM7 in the whole cohort breast cancer patients and the different molecular subtype cancersBack to article page